Publication Name	World Journal of Hepatology
Manuscript ID	18819
Country	Japan

Received	2015-04-28 16:43
Peer-Review Started	2015-05-04 11:58
To Make the First Decision	2015-07-17 16:31
Return for Revision	2015-07-21 10:05
Revised	2015-08-02 18:48
Second Decision	2015-09-02 10:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-09-08 15:48
Articles in Press	2015-09-08 15:48
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-14 15:23
Publish the Manuscript Online	2015-10-02 19:06

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Koichi Honda, Masataka Seike and Kazunari Murakami
Funding Agency and Grant Number
Corresponding Author	Koichi Honda, MD, PhD, Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita 879-5593, Japan. hondak@oita-u.ac.jp
Key Words	Hepatitis B; Nucleos(t)ide analogue; Liver cirrhosis; Lamivudine; Entecavir
Core Tip	We presented the benefits of nucleos(t)ide analogs (NUCs) treatments for HBV-related cirrhosis in this article. NUC treatments have been found to improve inflammation and fibrosis in the liver of cirrhotic patients. Moreover, even in patients with decom-pensated cirrhosis, liver function has improved in many cases. Furthermore, although NUC treatments can reduce the incidence of hepatocellular carcinoma (HCC), rates of HCC remain high in patients with cirrhosis. NUC treatments have been found to improve liver function and the survival of patients with HCC. Improved liver function was also achieved by providing NUC treatments for hepatitis B virus-related HCC when recurrent tumors developed. Therefore, it is important to select the most appropriate treatment method considering the alterations in liver function that may occur following NUC treatments.
Publish Date	2015-10-02 19:06
Citation	Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015; 7(22): 2404-2410
URL	http://www.wjgnet.com/1948-5182/full/v7/i22/2404.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i22.2404

Full Article (PDF)	WJH-7-2404.pdf
Full Article (Word)	WJH-7-2404.doc
Manuscript File	18819-Review.docx
Answering Reviewers	18819-Answering reviewers.pdf
Audio Core Tip	18819-Audio core tip.wav
Conflict-of-Interest Disclosure Form	18819-Conflict-of-interest statement.pdf
Copyright License Agreement	18819-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18819-Language certificate.pdf
Peer-review Report	18819-Peer-review(s).pdf
Scientific Misconduct Check	18819-Scientific misconduct check.pdf
Scientific Editor Work List	18819-Scientific editor work list.pdf